EXCOR® Pediatric VAD Anticoagulation IDE Investigational Plan
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 发起方
- 主要终点
- Number of all forms of stroke events reported using the Stanford Anti-Thrombotic Protocol.
研究概览
简要总结
The Berlin Heart EXCOR ventricular assist device received approval from the FDA as a bridge to transplantation for children in 2011. Successful bridge to transplantation or recovery in the IDE trial of the Berlin Heart EXCOR was 88% to 92%, but a high incidence of neurological injury was reported in this trial (29%).
Stroke remains the most important complication of Berlin Heart EXCOR support, with high mortality rates, and considerable long-term morbidity. The EXCOR IDE study incorporated a novel anticoagulation protocol (henceforth referred to as the Edmonton Anticoagulation Protocol). The preponderance of ischemic strokes in this study raised the question of whether the anticoagulation protocol was sufficiently intensive, as ischemic strokes in this setting are virtually always thromboembolic phenomena. In response to these data and to the experience at the investigator's institution, a novel anticoagulation protocol has been devised for use with the EXCOR (Stanford anticoagulation protocol).The purpose of this study is to perform a pilot evaluation of this protocol in a multi--center setting, to prepare for a randomized trial between this and a subsequent iteration of anticoagulation treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- — 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Severe heart failure (NYHA functional class IV, or Ross functional class IV if < age 6 years of age), refractory to optimal medical therapy
- •Patient deemed to be candidate for EXCOR implantation according to the clinical criteria employed by treating site
- •Listed or eligible for cardiac transplantation according to the criteria employed by the treating site
- •Two-ventricle circulation, including cardiomyopathy, repaired structural heart disease, or acquired heart disease
- •Age 0 to 18 years of age
- •Corrected gestational age ≥ 37 weeks
- •Weight ≥ 3 kg and ≤ 60 kg
- •Legal guardian (and patient if age-appropriate) understands the nature of the investigation, is willing to comply with the protocol and associated evaluations, and provides written informed consent and assent prior to the procedure.
排除标准
- •Support on ECMO for ≥10 days
- •Cardiopulmonary resuscitation (CPR) duration ≥ 30 minutes within 48 hours prior to device implantation
- •Body weight < 3.0 kg or BSA > 1.5 m2
- •Presence of mechanical aortic valve
- •Unfavorable or technically-challenging cardiac anatomy including single ventricle lesions, complex heterotaxy, and restrictive cardiomyopathy.
- •Evidence of intrinsic hepatic disease as defined by a total bilirubin level or ALT greater than 5 times the upper limit of normal for age, except in association with acute heart failure as determined by the site principal investigator
- •Evidence of intrinsic renal disease as defined by a serum creatinine greater than 3 times the upper limit of normal for age, except in association with acute heart failure as determined by the investigator
- •Hemodialysis or peritoneal dialysis (not including dialysis or continuous veno-venous hemofiltration (CVVH) for volume removal)
- •Evidence of intrinsic pulmonary disease (eg chronic lung disease, or ARDS) as defined by need for positive pressure ventilation, except in association with acute heart failure as determined by the principal investigator
- •Moderate or severe aortic and/or pulmonary valve insufficiency considered technically challenging to repair at the time of the device implantation as determined by the principal investigator
- •Apical VSD or other hemodynamically-significant lesion considered technically challenging to repair at the time of device implantation as determined by the principal investigator
- •Documented heparin induced thrombocytopenia (HIT) or idiopathic thrombocytopenia purpura (ITP) or other contraindication to anticoagulant/antiplatelet therapy
- •Documented coagulopathy (e.g. Factor VIII deficiency, disseminated intravascular coagulation) or thrombophilic disorder (e.g. Factor V Leiden mutation)
- •Hematologic disorder causing fragility of blood cells or hemolysis (e.g. sickle cell disease)
- •Platelets < 70,000/ml within 24 hours prior to device implantation
- •Active infection within 48 hours of implant (positive blood culture OR temperature > 38 degrees C AND wbc > 15,000/ml)
- •Documented human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)
- •Evidence of recent or life-limiting malignant disease
- •Stroke within past 30 days prior to enrollment, or congenital CNS malformation syndrome associated with increased risk of bleeding (e.g. arteriovenous malformation, moya moya)
- •Psychiatric or behavioral disease (e.g. antisocial disorder) with a high likelihood for non-adherence to the protocol and follow-up
- •Currently participating in another investigational device or drug trial and has not completed the required follow-up period for that study. EXCEPTION: Dual enrollment in PUMPKIN study is permitted.
- •Patient is pregnant or nursing
结局指标
主要结局
Number of all forms of stroke events reported using the Stanford Anti-Thrombotic Protocol.
时间窗: Up 90 days
To test the effectiveness of the Stanford Anti-Thrombotic protocol.
Number of major bleeding adverse events reported using the Stanford Anti-Thrombotic Protocol.
时间窗: Up to 90 days
To test the safety of the Stanford Anti-Thrombotic Protocol.
次要结局
未报告次要终点
研究者
David N. Rosenthal
Professor of Pediatrics
Stanford University